abc biopply collaborates with Pathways Preclinical Partners to bring organoid technology to their network

Under this initiative, US based Pathways Preclinical Partners will support the broader introduction of abc biopply’s advanced humanized disease model technology throughout its professional network introducing it to programs that drive translational impact for life-science innovators.

abc biopply AG, a Swiss biotech pioneer, offers highly predictive preclinical CRO services grounded in its proprietary 3D CoSeedis Multi-Organoid in Chip Technology, enabling scalable and standardized humanized multi-organoid disease models across therapeutic areas such as oncology, neurology, hepatology and others. These models were created to close the translational gap between simple, high‑throughput 2D and 3D in vitro systems and complex in vivo models with low throughput. A major limitation in predictability today results from the lack of translational applicability of the results from the two model types. abc biopply’s new NAM technology provides early accessibility of fully scalable, complex models with high throughput capabilities, enhancing physiological relevance while reducing the consumption of time, costs, and animal resources.

Path2P is a strategic consulting firm dedicated to guiding pharmaceutical and biotech companies through complex development pathways, from late-stage preclinical work to first-in-human clinical readiness, by providing regulatory, commercialization, and business development strategies tailored to scientific goals and market realities. Its expert team includes former regulatory officials and industry leaders who help clients make informed decisions and accelerate their path to patients.

“Pathways is excited to bring abc biopply’s transformative organoid technology to our network and contribute to the future of human-relevant preclinical innovation,” said Jae Sly, MBA, PhD, Chairman & CEO of Pathways Preclinical Partners. “This collaboration highlights our shared commitment to empowering biotech and pharmaceutical innovators with tools and strategies that de-risk development and contribute to meaningful patient impact.”

By supporting the accessibility and understanding of advanced humanized preclinical models, the collaboration aims to help scientists, developers, and decision-makers explore more physiologically relevant alternatives in the drug discovery process, while fostering connections that accelerate translational success.

“We are looking forward to working alongside Pathways to bring our technology into new scientific and commercial forums,” said Dr. Arne Faisst, Founder & CEO of abc biopply AG. “Our shared vision around improving preclinical predictability aligns closely with global needs for more humanized approaches in therapeutic development.”

The collaboration underscores the increasing importance of innovative preclinical platforms and strategic guidance in driving efficiency and confidence across drug development pipelines. By bridging expertise in advanced modeling and global networking, both organizations are positioned to impact how next-generation therapies are evaluated and advanced toward clinical application.